COMP <GO>
AMRX vs UNH // FORWARD P/E MULTIPLE
Amneal Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: AMRX 7
— UNH 8
▲ FORWARD P/E MULTIPLE LEADER: UNH
LAST: $21.51 (+0.75%) • MKT CAP: $7.44B
forward-pe
96.0x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
forward-pe
17.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 88.57% | -51.67 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 11.47% | +2.63 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.4x | 16.4x | +4.95 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 6.48% | -2.85 | UNH | /fcf-yield <GO> |
| Operating Margin | 13.10% | 4.82% | +8.28 | AMRX | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 3.14% | -0.74 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 6.46% | +1.54 | AMRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 3.12 | +0.71 | AMRX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 56.0 | +11.60 | AMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.33 | +0.75 | AMRX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 96.0x | 17.1x | +78.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.44B | $364.66B | -$357.22B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | UNH REV | AMRX GROSS % | UNH GROSS % | AMRX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $447.57B | 36.9% | 88.7% | $269.9M | $16.07B |
| FY 2024 | $2.79B | $400.28B | 36.5% | 88.3% | $243.2M | $20.70B |
| FY 2023 | $2.39B | $371.62B | 44.0% | 89.6% | $237.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
UNH // BETA 0.33